Purdue Pharma L.P. To Present Data Regarding Long-Term Opioid Therapy At American Pain Society Annual Meeting

STAMFORD, Conn., May 8, 2013 – Purdue Pharma L.P. will present three posters addressing the potential for long-term opioid therapy (LTO) to treat chronic cancer and non-cancer pain during the American Pain Society’s annual meeting May 8-11 in New Orleans.

The complete schedule for the three posters being presented at the APS meeting follows:

  • Thursday, May 9, 9:30-11:00 a.m., Poster 407“Long-term efficacy and safety of opioid therapy for chronic non-cancer pain: evidence from randomized and open-label studies.”
    R. Matsuno, L. Wallace, R. Glanzman, B. Martell, P. Coplan
  • Thursday, May 9, 9:30-11:00 a.m., Poster 399“Duration of use of extended-release oxycodone and morphine among adults with cancer and non-cancer pain.”
    A. DeVeaugh-Geiss, H. Chilcoat, P. Coplan
  • Friday, May 10, 9:30-11:00 a.m., Poster 408“What’s the difference? Within-patient versus between-patient designs to evaluate the effects of long-term opioid therapy.”
    R. Matsuno, L. Wallace, R. Glanzman, B. Martell, P. Coplan

The first poster, “Long-term efficacy and safety of opioid therapy for chronic non-cancer pain: evidence from randomized and open-label studies analyzed data from two randomized clinical trials and 40 open-label extension trials, most of which were six months or longer. The data describes the long-term safety and efficacy of opioid analgesic therapy for chronic non-cancer pain.

The second poster, “Duration of use of extended-release oxycodone and morphine among adults with cancer and non-cancer pain,” used data from a national insurance database and assessed the duration of use of extended-release morphine vs. extended-release (ER) oxycodone among cancer and non-cancer patients. Overall, most patients dispensed a new ER oxycodone or ER morphine prescription had a non-malignant pain condition. Fewer than one in five of these patients received continuous treatment for more than six months.

The third poster is titled, “What’s the difference? Within-patient versus between-patient designs to evaluate the effects of long-term opioid therapy.” Purdue conducted a literature search of observational studies evaluating LTO therapy including both within patient (single-arm open-label trials and open-label extensions-to-RCTs) and between-patient (cross-sectional and cohort studies) designs and compared their results regarding efficacy, safety, and function/quality of life. Any apparent value of LTO therapy may be influenced by the type of observational studies referenced.

“Purdue recognizes the importance of proper patient selection and monitoring when considering how, when and to whom opioid pain medications should be prescribed,” said Gary L. Stiles, M.D., vice president of research and development at Purdue. “It is important to take into account the diversity, duration, and impact of pain on the patient, as well as the potential for misuse, abuse and addiction. There is no “one-size-fits-all” approach to treating a diverse patient population.”

The authors of these posters are all full-time employees of Purdue Pharma L.P. and the reviews were funded by the Company.

# # #

About Purdue Pharma L.P.
Purdue Pharma L.P. and its associated U.S. companies are privately held pharmaceutical companies known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue Pharma is engaged in the research, development, production and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.

Contact:
Libby Holman
Associate Director
Public Affairs
Tel: 203-588-7670
Cell: 203-609-1291
Email: libby.holman@pharma.com

The prescription and illicit opioid abuse crisis is a multifaceted public health challenge, and as a manufacturer of prescription opioids, we have a responsibility to join the fight. At Purdue we are committed to lead our industry in helping address our nation's prescription and illicit opioid abuse crisis.

There is more to come – as we continue to work with partners and experts to deliver solutions. Below you will find additional information about our efforts.

Read our open letter about the opioid crisis.